ResQ Pharma, Inc., a Chicago-based pharmaceutical company developing and commercializing innovative drug therapies, today announced that it has received a PDUFA (Prescription Drug User Fee Act) date ...

Unicycive, which is seeking an FDA green light for oxylanthanum carbonate to treat hyperphosphatemia in patients with chronic kidney disease who are on dialysis, Monday said the agency set a target ...

I have long held the belief that digital therapeutics will be prescribed alongside drugs to improve patient outcomes, leading ...

FDA sets PDUFA Action Date of June 28, 2025 ...